In light of the large number of studies published since the 2004 update of Schizophrenia
Patient Outcomes Research Team psychopharmacological treatment recommendations, we …

Abstract The Schizophrenia Patient Outcomes Research Team (PORT) project has played a
significant role in the development and dissemination of evidence-based practices for …

Background: A panel of academic psychiatrists and pharmacists, clinicians from the Texas
public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to …

Schizophrenia is a chronic neuropsychiatric disorder affecting an estimated 3.5 million
individuals in the United States. 1 It is characterized by a combination of positive symptoms …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults
across different stages, phases, and symptom domains. Method: Guidelines were developed …

Background The question of which antipsychotic drug should be preferred for the treatment
of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

This systematic review and meta-analysis examined predictors of successful antipsychotic
dose reduction in schizophrenia. Prospective clinical trials and randomized controlled trials …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …